Presyo ng Stock at Balita sa Neurocrine Biosciences, Inc (NBIX)

Outlook: 63.6% bullish·0.0% bearish

Pumunta sa pagsusuri

NBIX:NASDAQ

Neurocrine Biosciences, Inc

$136.44

+0.39%

(+0.53) 1D

Okt 15, 2:06:16 PM GMT-4 · USD

Lahat ng simbolo

	Simbolo	Presyo	Palitan	% ng Pagbabago

Bumubuo ng mga nangungunang insight para sa NBIX...

Buksan

$137.26

Mataas

$138.23

Mababa

$135.55

Mkt. cap

13.87B

Avg. na dami

1.31M

Dami

583.42K

P/E ratio

20.00

Mataas nang 52-wk

$186.12

Mababa nang 52-wk

$122.14

EPS

$6.82

Beta

0.40

Mga natitirang share

101.65M

Bilang ng mga empleyado

Buksan

$137.26

Mataas

$138.23

Mababa

$135.55

Mkt. cap

13.87B

Avg. na dami

1.31M

Dami

583.42K

P/E ratio

20.00

Mataas nang 52-wk

$186.12

Mababa nang 52-wk

$122.14

EPS

$6.82

Beta

0.40

Mga natitirang share

101.65M

Bilang ng mga empleyado

Mga kaugnay na stock

Madrigal Pharmaceuticals Inc

Mga balita at kwento

Mula sa mga source sa web at partner sa balita

ad-hoc-news.de

12 minuto ang nakalipas

RBC keeps USD 187.00 target for Neurocrine Biosciences stock

Stock Titan

26 minuto ang nakalipas

JPMorgan reports a passive stake in Neurocrine Biosciences (NBIX)

Investing.com

1 araw ang nakalipas

TD Cowen reiterates Neurocrine Bio stock rating on growth outlook

Zacks

1 araw ang nakalipas

Why Neurocrine Biosciences (NBIX) is a Top Value Stock for the Long-Term

Profile

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia. The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia

Tungkol sa Neurocrine Biosciences, Inc

CEOKevin C. Gorman

Mga Empleyado2.5K

Itinatag1992

HeadquartersSan Diego, California, Estados Unidos

Sektor-

Websiteneurocrine.com

Mga rating ng analyst

Batay sa 26 (na) analyst na nagbigay ng mga rating ng stock sa NBIX sa nakalipas na 3 buwan

Strong buy

Pagbili

Pag-hold

Pagbebenta

12 buwang forecas

Batay sa 26 (na) analyst sa Wall Street na nag-aalok ng mga target na presyo sa loob ng 12 buwan para sa NBIX sa nakalipas na 3 buwan.

Pinakamataas

Kasalukuyan $136.44

$253.00 (+85.43%)

Average

$207.28 (+51.92%)

Pinakamababa

$150.00 (+9.94%)

Analyst	Rekomendasyon	Aksyon	Target na presyo	Inaasahan	Petsa
Mohit Bansal Wells Fargo	Buy	Maintained	$200.00	+46.6%	10/13/2026
Brian Abrahams RBC Capital	Buy	Maintained	$187.00	+37.1%	10/13/2026
Evan Seigerman BMO Capital	Hold	Maintained	$150.00	+9.9%	10/12/2026
Tazeen Ahmad Bank of America Securities	Buy	Reiterated	$214.00	+56.8%	10/09/2026
David Amsellem Piper Sandler	Buy	Reiterated	$210.00	+53.9%	10/09/2026
Delma Caiati Guggenheim	Buy	Initiated	$207.00	+51.7%	10/05/2026
Yatin Suneja Guggenheim	Buy	Initiated	$207.00	+51.7%	10/05/2026
Akash Tewari Jefferies	Buy	Maintained	$220.00	+61.2%	09/29/2026
Unknown Analyst Jefferies	Buy	Maintained	$220.00	+61.2%	09/29/2026
Ashwani Verma UBS	Buy	Reiterated	$214.00	+56.8%	09/28/2026
Jeffrey Walch Bernstein	Buy	Maintained	$218.00	+59.8%	09/25/2026
Unknown Analyst CCB Intl.	Buy	Initiated	$188.00	+37.8%	09/18/2026
Sean Laaman Morgan Stanley	Hold	Reiterated	$183.00	+34.1%	09/11/2026
Yigal Nochomovitz Citi	Buy	Maintained	$253.00	+85.4%	09/04/2026
Cory Kasimov Evercore ISI	Buy	Maintained	$215.00	+57.6%	08/17/2026
David Hoang Deutsche Bank	Hold	Reiterated	$165.00	+20.9%	08/13/2026
Anupam Rama J.P. Morgan	Buy	Maintained	$217.00	+59%	08/06/2026
Laura Chico Wedbush	Buy	Maintained	$194.00	+42.2%	08/03/2026
Sumant Kulkarni Canaccord Genuity	Buy	Reiterated	$210.00	+53.9%	08/03/2026
Danielle Brill Truist Financial	Buy	Maintained	$213.00	+56.1%	08/03/2026
Andrew Fein H.C. Wainwright	Buy	Maintained	$215.00	+57.6%	07/31/2026
Myles Minter William Blair	Buy	Reiterated	-	-	07/31/2026
Jay Olson Oppenheimer	Buy	Maintained	$230.00	+68.6%	07/31/2026
Joshua Schimmer Cantor Fitzgerald	Buy	Reiterated	$215.00	+57.6%	07/30/2026
Brian Skorney Robert W. Baird	Buy	Maintained	$225.00	+64.9%	07/31/2026
Paul Matteis Stifel Nicolaus	Buy	Maintained	$215.00	+57.6%	07/31/2026
Ami Fadia Needham	Buy	Reiterated	$204.00	+49.5%	07/31/2026
Phil Nadeau TD Cowen	Buy	Reiterated	$220.00	+61.2%	07/31/2026
Corinne Johnson Goldman Sachs	Buy	Initiated	$213.00	+56.1%	06/02/2026
Unknown Analyst Bernstein	Buy	Initiated	$221.00	+62%	05/21/2026
Nevin Varghese RBC Capital	Buy	Reiterated	$180.00	+31.9%	05/11/2026
Unknown Analyst Guggenheim	Buy	Reiterated	$175.00	+28.3%	05/06/2026
Rudy Li Wolfe Research	Buy	Reiterated	$160.00	+17.3%	04/06/2026
Daniel Giraldo Bank of America Securities	Buy	Reiterated	$199.00	+45.9%	04/06/2026

Lahat ng value sa USD	Set 2025	Dis 2025	Mar 2026	Hun 2026
Kita	794.90M	805.50M	814.50M	959.00M
Gastusin sa mga naibentang produkto	264.00M	275.80M	310.00M	346.70M
Halaga ng kita	264.00M	275.80M	310.00M	346.70M
Mga gastos sa pananaliksik at pag-develop	-	-	-	-
Kabuuang gastos sa pananaliksik at pag-develop	-	-	-	-
Mga gastos sa pagbebenta, pangkalahatan, at admin	291.60M	302.50M	318.50M	383.10M
Gastos sa pagpapatakbo	291.60M	302.50M	318.50M	399.50M
Kabuuang gastos sa pagpapatakbo	555.60M	578.30M	628.50M	746.20M
Kita sa pagpapatakbo	239.30M	227.20M	186.00M	212.80M
Iba pang hindi kita sa pagpapatakbo	-	-	-	-
EBT na may mga hindi karaniwang item	291.80M	239.40M	246.80M	162.20M
EBT na hindi kasama ang mga hindi karaniwang item	261.50M	253.00M	214.10M	222.30M
Gastos sa buwis sa kita	82.30M	85.70M	48.90M	17.80M
Epektibong rate ng buwis	28.20%	35.80%	19.81%	10.97%
Iba pang gastos sa pagpapatakbo	-	-	-	-
Net na kita	209.50M	153.70M	197.90M	144.40M
Margin ng kabuuang kita	26.36%	19.08%	24.30%	15.06%
Kita bawat share	2.17	1.88	1.94	2.85
Kita sa interes at investment	22.20M	25.80M	28.10M	12.40M
Gastos sa interes	-	-	-	-2.90M
Mga net na gastos sa interes	22.20M	25.80M	28.10M	9.50M
Mga singil sa depreciation at amortization	-	-	-	-
EBITDA	247.00M	234.70M	193.30M	237.60M
Kita o pagkalugi mula sa pagbebenta ng mga asset	-	-	-28.60M	-

Finance

Magtanong ng kahit na ano